However, there was a significant increase in the incidence of CRS for patients who used G-CSF than those did not in high-BM tumor burden group (P = 0.037), without significant differences in severity of CRS and incidence and severity of NEs (Table 2). The gene discussed is CSF3; the disease is congenital rubella syndrome.